New antiepileptic drugs, cost-efficacy analysis

Objective: to optimize pharmacotherapy in patients with epilepsy and to evaluate the clinical and cost-effectiveness of its therapy with the new antiepileptic drugs (AED): levetiracetam, lamotrigine, topiramate, and oxcarbazepine.Patients and methods. The study enrolled 134 patients (women, 69.03%;...

Full description

Bibliographic Details
Main Authors: P. N. Vlasov, N. V. Orekhova, T. I. Konovalova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2014-01-01
Series:Неврология, нейропсихиатрия, психосоматика
Subjects:
Online Access:https://nnp.ima-press.net/nnp/article/view/226
_version_ 1797876517958582272
author P. N. Vlasov
N. V. Orekhova
T. I. Konovalova
author_facet P. N. Vlasov
N. V. Orekhova
T. I. Konovalova
author_sort P. N. Vlasov
collection DOAJ
description Objective: to optimize pharmacotherapy in patients with epilepsy and to evaluate the clinical and cost-effectiveness of its therapy with the new antiepileptic drugs (AED): levetiracetam, lamotrigine, topiramate, and oxcarbazepine.Patients and methods. The study enrolled 134 patients (women, 69.03%; men, 30.97%) with different types of seizures, who had previously received antiepileptic therapy. The patients visited their physician at least twice; after correcting therapy by an epileptologist, the mono- or polytherapy regimen included new AEDs. The patients' mean age was 29.8±8.7 years; disease duration was 13.01±6.7 years; mean age at onset was 16.8±8.5 years. In the groups of working and nonworking patients with different types of seizures, the authors calculated the cost of epilepsy therapy, by taking into account the use of new AEDs and the pharmacoeconomic index "cost-benefit" before and after therapy optimization.Results. When the new AEDs were incorporated into the therapy, the low incidence rate of seizures following a year averaged 75 to 92%. The index cost-effectiveness was decreased by 2—3 times in all types of seizures when the new AEDs were used despite the increased direct cost of treatment. Also, there was a significant reduction in the cost of epilepsy treatment in practically all the groups under study. The findings suggest that the index cost-efficacy directly depends on the rational choice of an AED in an adequate dose. Rational therapy with the new AEDs makes it possible to reduce not only the total cost of epilepsy treatment, but also to lower the index cost-efficacy.
first_indexed 2024-04-10T02:04:32Z
format Article
id doaj.art-b74b70faefbf4c5ab06e8a423a2a1707
institution Directory Open Access Journal
issn 2074-2711
2310-1342
language Russian
last_indexed 2024-04-10T02:04:32Z
publishDate 2014-01-01
publisher IMA-PRESS LLC
record_format Article
series Неврология, нейропсихиатрия, психосоматика
spelling doaj.art-b74b70faefbf4c5ab06e8a423a2a17072023-03-13T08:42:12ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422014-01-0141S283410.14412/2074-2711-2012-2495226New antiepileptic drugs, cost-efficacy analysisP. N. Vlasov0N. V. Orekhova1T. I. Konovalova2Department of Nervous Diseases, Therapeutic Faculty, Moscow State University of Medicine and DentistryDepartment of Nervous Diseases, Therapeutic Faculty, Moscow State University of Medicine and DentistryDepartment of Nervous Diseases, Therapeutic Faculty, Moscow State University of Medicine and DentistryObjective: to optimize pharmacotherapy in patients with epilepsy and to evaluate the clinical and cost-effectiveness of its therapy with the new antiepileptic drugs (AED): levetiracetam, lamotrigine, topiramate, and oxcarbazepine.Patients and methods. The study enrolled 134 patients (women, 69.03%; men, 30.97%) with different types of seizures, who had previously received antiepileptic therapy. The patients visited their physician at least twice; after correcting therapy by an epileptologist, the mono- or polytherapy regimen included new AEDs. The patients' mean age was 29.8±8.7 years; disease duration was 13.01±6.7 years; mean age at onset was 16.8±8.5 years. In the groups of working and nonworking patients with different types of seizures, the authors calculated the cost of epilepsy therapy, by taking into account the use of new AEDs and the pharmacoeconomic index "cost-benefit" before and after therapy optimization.Results. When the new AEDs were incorporated into the therapy, the low incidence rate of seizures following a year averaged 75 to 92%. The index cost-effectiveness was decreased by 2—3 times in all types of seizures when the new AEDs were used despite the increased direct cost of treatment. Also, there was a significant reduction in the cost of epilepsy treatment in practically all the groups under study. The findings suggest that the index cost-efficacy directly depends on the rational choice of an AED in an adequate dose. Rational therapy with the new AEDs makes it possible to reduce not only the total cost of epilepsy treatment, but also to lower the index cost-efficacy.https://nnp.ima-press.net/nnp/article/view/226epilepsylevetiracetamlamotriginetopiramateoxcarbazepinecost-efficacy
spellingShingle P. N. Vlasov
N. V. Orekhova
T. I. Konovalova
New antiepileptic drugs, cost-efficacy analysis
Неврология, нейропсихиатрия, психосоматика
epilepsy
levetiracetam
lamotrigine
topiramate
oxcarbazepine
cost-efficacy
title New antiepileptic drugs, cost-efficacy analysis
title_full New antiepileptic drugs, cost-efficacy analysis
title_fullStr New antiepileptic drugs, cost-efficacy analysis
title_full_unstemmed New antiepileptic drugs, cost-efficacy analysis
title_short New antiepileptic drugs, cost-efficacy analysis
title_sort new antiepileptic drugs cost efficacy analysis
topic epilepsy
levetiracetam
lamotrigine
topiramate
oxcarbazepine
cost-efficacy
url https://nnp.ima-press.net/nnp/article/view/226
work_keys_str_mv AT pnvlasov newantiepilepticdrugscostefficacyanalysis
AT nvorekhova newantiepilepticdrugscostefficacyanalysis
AT tikonovalova newantiepilepticdrugscostefficacyanalysis